CORT Corcept Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CORT

Price (delayed)

$22.95

Market cap

$2.38B

P/E Ratio

22.5

Dividend/share

N/A

EPS

$1.02

Enterprise value

$2.24B

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® ...

Highlights
Corcept Therapeutics's debt has shrunk by 87% YoY and by 33% QoQ
The P/E is 20% less than the last 4 quarters average of 28.1
The quick ratio is down by 39% year-on-year but it is up by 23% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.corcept.com
Peers: JNJ BMY PFE LLY

Key stats

What are the main financial stats of CORT
Market
Shares outstanding
103.52M
Market cap
$2.38B
Enterprise value
$2.24B
Valuations
Price to earnings (P/E)
22.5
Price to book (P/B)
4.67
Price to sales (P/S)
4.93
EV/EBIT
21.01
EV/EBITDA
20.55
EV/Sales
4.64
Earnings
Revenue
$482.38M
EBIT
$106.64M
EBITDA
$109M
Free cash flow
$126.9M
Per share
EPS
$1.02
Free cash flow per share
$1.23
Book value per share
$4.92
Revenue per share
$4.66
TBVPS
$6
Balance sheet
Total assets
$621.52M
Total liabilities
$114.81M
Debt
$151,000
Equity
$506.71M
Working capital
$354.13M
Liquidity
Debt to equity
0
Current ratio
4.39
Quick ratio
3.92
Net debt/EBITDA
-1.24
Margins
EBITDA margin
22.6%
Gross margin
98.7%
Net margin
21.9%
Operating margin
22.2%
Efficiency
Return on assets
17.9%
Return on equity
22%
Return on invested capital
34.4%
Return on capital employed
20.6%
Return on sales
22.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CORT stock price

How has the Corcept Therapeutics stock price performed over time
Intraday
1.28%
1 week
-2.38%
1 month
-5.36%
1 year
3.85%
YTD
-29.34%
QTD
-8.89%

Financial performance

How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$482.38M
Gross profit
$475.89M
Operating income
$107.28M
Net income
$105.5M
Gross margin
98.7%
Net margin
21.9%
The operating margin has contracted by 21% YoY
The gross profit is up by 20% year-on-year and by 7% since the previous quarter
The revenue rose by 20% year-on-year and by 7% since the previous quarter
CORT's net income is up by 16% QoQ and by 4.2% YoY

Growth

What is Corcept Therapeutics's growth rate over time

Valuation

What is Corcept Therapeutics stock price valuation
CORT P/E details
P/E
22.5
P/B
4.67
P/S
4.93
EV/EBIT
21.01
EV/EBITDA
20.55
EV/Sales
4.64
The P/E is 20% less than the last 4 quarters average of 28.1
The EPS has grown by 16% since the previous quarter and by 7% year-on-year
The stock's price to book (P/B) is 17% less than its last 4 quarters average of 5.6 and 7% less than its 5-year quarterly average of 5.0
The company's equity rose by 10% QoQ
The revenue rose by 20% year-on-year and by 7% since the previous quarter
CORT's P/S is 19% below its 5-year quarterly average of 6.1 and 18% below its last 4 quarters average of 6.0

Efficiency

How efficient is Corcept Therapeutics business performance
CORT's ROIC is up by 26% year-on-year and by 15% since the previous quarter
The return on sales has declined by 21% year-on-year
The return on equity is up by 16% since the previous quarter
CORT's return on assets is up by 14% since the previous quarter but it is down by 8% year-on-year

Dividends

What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CORT.

Financial health

How did Corcept Therapeutics financials performed over time
The total liabilities has grown by 41% YoY but it has contracted by 13% from the previous quarter
The quick ratio is down by 39% year-on-year but it is up by 23% since the previous quarter
Corcept Therapeutics's debt is 100% lower than its equity
Corcept Therapeutics's debt has shrunk by 87% YoY and by 33% QoQ
The company's equity rose by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.